Sanofi-Aventis Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Sanofi-Aventis (formerly Sanofi-Synthelabo) on November 5, 2004. The filing serves to disclose two significant regulatory approvals received in early November 2004 regarding oncology treatments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory milestones rather than financial performance data.
Material Changes and Regulatory Approvals
- European Union Approval: On November 4, 2004, the European Union approved Taxotere (docetaxel) for the treatment of prostate cancer.
- US FDA Approval: On November 5, 2004, the United States Food and Drug Administration approved Eloxatin (oxaliplatin for injection) for the adjuvant (postsurgical) treatment of colon cancer.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of these specific approvals. The filing does not contain forward-looking guidance, risk factors, or discussion of contingencies beyond the successful regulatory outcomes for the named products.
Key Facts for Investor Verification
- Verify the commercial launch timelines for Taxotere in the EU for prostate cancer and Eloxatin in the US for colon cancer.
- Confirm the specific indications and dosing regimens approved in the respective regions.
- Assess the potential revenue impact of these new indications on Sanofi-Aventis's oncology portfolio.